

INVESTOR WEBINAR

Highlights:

- Echo IQ will hold an investor webinar at 11:00am AEDT on Wednesday 6 November 2024 to introduce incoming Chief Executive Officer, Mr. Dustin Haines
- Webinar will be hosted by Chief Commercial Officer, Mr Deon Strydom and Chief Operating Officer, Mr Philip Woolff
- Webinar follows the Company's announcement of FDA Clearance for its EchoSolv-AS solution
- Additional details to be provided around Company's regulatory and commercialisation pathways

Sydney: Artificial Intelligence and Medical Technology company Echo IQ Limited ("the Company") (ASX:EIQ) is pleased to advise that it will host an investor webinar at 11:00am AEST on Wednesday, 6 November 2024. The webinar will introduce investors to Mr Dustin Haines, who will be commencing in his role as Echo IQ Chief Executive Officer from 10 January 2025.

Mr Deon Strydom, Chief Commercial Officer, will also provide an update to investors on the opportunities for commercialisation following the Company's recent announcement of FDA clearance for its EchoSolv-AS solution (refer ASX announcement: 8 October 2024).

The briefing will be followed by a Q&A Session. Questions can be submitted now to investors@echoiq.ai.

Anyone wishing to attend the webinar must register in advance using the below link.

Webinar Details

Date and time: 11:00am AEDT (08:00am AWST) on Wednesday, 6 November 2024

Register via: https://us02web.zoom.us/webinar/register/WN_n2g4wXRiRsy3SSqFDZ8dw#/registration

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:

Philip Woolff, Chief Operating Officer
philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.